BioSpace News Archive

SPACs – special purpose acquisition companies – have lost their luster and may never regain it. BioSpace spoke with Neal Gerber Eisenberg’s Gregory D. Grove.

Ascentage Pharma announced that it has released results from a Phase I study of the company’s novel Bcl-2-selective inhibitor lisaftoclax in Chinese patients with relapsed/refractory non-Hodgkin lymphoma at the 2022 European Hematology Association Hybrid Congress.

Shimadzu Corporation will commence worldwide sales of its flagship newest version of its Trinias™ angiography system.

Ascletis Pharma Inc., announces the expansion of management team with appointment of Mr. John P. Gargiulo, former North America President and CEO of Daiichi Sankyo, as Chief Business Officer.

Day One Biopharmaceuticals announced positive initial data from the first 22 Response Assessment for Neuro-Oncology -evaluable patients enrolled in the ongoing, open-label, single-arm, pivotal Phase 2 FIREFLY-1 clinical trial.

Innovent Biologics, Inc. and IASO Biotherapeutics jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel, a fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma, was presented in the form of an oral presentation at the 27th European Hematology Association Annual Meeting in Vienna on June 9-12, 2022.

IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel, a fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma, was presented in the form of an oral presentation at the 27th European Hematology Association Annual Meeting in Vienna on June 9-12, 2022.

Gracell Biotechnologies Inc. announced the updated clinical data from a multicenter study evaluating GC012F, the Company’s autologous CAR-T therapeutic candidate dual-targeting B-cell maturation antigen and CD19, for the treatment of relapsed/refractory multiple myeloma.

Innovent Biologics, Inc. announces that the results of high-dose cohorts in a phase 1 clinical trial of mazdutide, a glucagon-like petide-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity are presented as an on-demand poster at ENDO 2022.

Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced that the first patient has been dosed in the Company’s US Phase IIa clinical trial of KPG-818, an orally bioavailable NeoMIDESTM molecular glue, for the treatment of systemic lupus erythematosus.